YN14
YN14 is a KRASG12C proteolysis targeting chimera (PROTAC) . YN14 is highly potent and selective KRASG12C degrader and induces a stable KRASG12C: YN14: VHL ternary complex with low binding free energy (ΔG) . YN14 has antiproliferative effects and significantly inhibits KRASG12C-mutant cancer cell growth. YN14 leads to tumor regression with tumor growth inhibition (TGI%) rates more than 100 % in the MIA PaCa-2 xenograft model.
Product Specifications
UNSPSC
12352005
Target
PROTACs; Ras
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway; PROTAC
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/yn14.html
Purity
99.0800
Solubility
10 mM in DMSO
Smiles
Molecular Formula
C62H75F2N11O7S
Molecular Weight
1156.39
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
IMPA2 (Inositol monophosphatase 2, IMP 2, IMPase 2, Inositol-1(or 4)-monophosphatase 2, Myo-inositol monophosphatase A2, IMPA2, IMP18P) (MaxLight 550)
IMPA2 (Inositol monophosphatase 2, IMP 2, IMPase 2, Inositol-1(or 4)-monophosphatase 2, Myo-inositol monophosphatase A2, IMPA2, IMP18P) (MaxLight 550)
Mouse IgG1 Isotype Control, FITC Conjugated mAb
Mouse IgG1 Isotype Control, FITC Conjugated mAb
Mouse IgG1 Isotype Control, FITC Conjugated mAb